Navigation Links
Delcath Enters Agreement to Sell 869,565 Units
Date:6/10/2009

NEW YORK, June 10 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP(TM)) System for the treatment of cancers of the liver, today announced that it has entered into a definitive agreement to sell 869,565 units, each unit consisting of one of the Company's common shares and a warrant to purchase 1.2 common shares, for gross proceeds of approximately $3 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering with a single institutional investor. The investor has agreed to purchase the units at a purchase price of $3.45 per unit. The warrants, which represent the right to acquire an aggregate of up to 1,043,478 common shares, will be exercisable at any time on or after the closing of the transaction and prior to the fifth anniversary of the closing of the transaction at an exercise price of $3.99 per share, which was 110% of the closing bid price of the Company's common shares on the Nasdaq Capital Market on June 9, 2009. The transaction is expected to close on or about June 15, 2009, subject to the satisfaction of customary closing conditions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Piper Jaffray & Co. acted as sole placement agent for the offering.

The Company is offering the securities in this transaction pursuant to an effective shelf registration statement and a registration statement filed pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended. The offering is being made only by means of a prospectus supplement. Copies of the
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
2. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
3. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Delcath Systems Granted Third Orphan Drug Designation
7. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
8. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Custom Computer Specialists, Inc. ("Custom"), a leading healthcare IT ... of the Primary Care Development Corporation,s ("PCDC") Corporate Circle. ... support of PCDC,s mission to expand access to primary ... in 1993, PCDC has been a key force of ... over 100 completed primary care projects, valued at over ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
(Date:6/29/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, ... that a collaboration led by the Icahn School of ... the first comprehensive analysis of a diploid human genome ... and genome mapping. This study, published today in ... contiguous diploid human genome assembly obtained without using inference-based ...
(Date:6/29/2015)... MO (PRWEB) , ... June 29, 2015 , ... The ... – July 16 and for the fourth year in a row, will bring top ... changes are taking place at the intersection of data and technology. The event is ...
Breaking Biology Technology:Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3
... , , , , ... MON ) R&D pipeline is on the verge of ... improved yield for growers and has the company poised to meet ... executive officer and president, will tell investors today. , , ...
... August 13 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader in the field ... of 2009. , , Highlights, - ... in Canada following two previous clinical trials, - ... a clinically important health benefit, accomplished by a significant, ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... its financial results for the second quarter ended June 30, ... pleased to report in April that the FDA accepted Auxilium,s ... Dupuytren,s disease and we are looking forward to the Arthritis ...
Cached Biology Technology:Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7Amsterdam Molecular Therapeutics Reports Half Year Results 2009 2Amsterdam Molecular Therapeutics Reports Half Year Results 2009 3Amsterdam Molecular Therapeutics Reports Half Year Results 2009 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... -- This report analyzes the worldwide markets for Immunoassay ... which includes Immunoassay Analyzers and Reagents: Enzyme Immunoassay Systems, ... and Nephelometric Immunoassay Systems. The report provides separate comprehensive ... Japan , Europe ... America , and Rest of World. Annual estimates ...
(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... as the 2007 winner of the ALPSP/Charlesworth Award for ... a significantly innovative approach to any aspect of scholarly ... years award was RSC Project Prospect from the Royal ... semantics into chemical science publishing. RSC Project Prospect journals ...
... of HIV research through his rational approach to trying to ... method is based on gaining an understanding of the molecular ... sites on the virus that the antibodies target a ... molecules used in an HIV-1 vaccine. He has published ...
... Washington, DC September 13, 2007 One of the 2007 ... sponsored by ASM will be presented to Hung Ton-That, ... and Structural Biology, University of Connecticut Health Center. ... in microbiology and infectious disease. Dr. Ton-Thats ...
Cached Biology News:RSC Project Prospect scoops prestigious award 2
...
Request Info...
... Cultrex High Protein Concentration Basement Membrane ... use in in vivo applications where ... times, increased gel strength, and elevated ... has the advantage of lot-to-lot consistency ...
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
Biology Products: